Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Releviate Therapeutics General Information
RLVT‑903, a human monoclonal antibody targeting MMP‑9, has entered Phase I clinical trials for peripheral and diabetic neuropathies. The company’s approach offers a first-in-class alternative to opioids by directly inhibiting key enzymes implicated in chronic and acute neuropathic pain. Preclinical data support high specificity and reduced off-target effects compared to previous small-molecule inhibitors. No published late-stage results yet.
Contact Information
Primary Industry
Biotech
Corporate Office
San Diego, California
United States
United States
Drug Pipeline
Phase 2
Key Partnerships
University of California Riverside — exclusive license for core antibodies technology developed at UCR and Duke University.
Releviate Therapeutics Funding
No funding data available
To view Releviate Therapeutics's complete valuation and funding history, request access »